Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809623 · ClinicalTrials.gov registry record · Phase 1
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04809623 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 3 participants.
The verdict
NCT04809623, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG Edecesertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04809623
The ClinicalTrials.gov registry entry for NCT04809623 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04809623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04809623 about?
NCT04809623 is a clinical study titled "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)". The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).
What is the current status of trial NCT04809623?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-09-01. Estimated completion is 2022-10-18.
What interventions are being tested in trial NCT04809623?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), Edecesertib (DRUG).
Who is sponsoring clinical trial NCT04809623?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.